NASDAQ$CYRX

CryoPort Inc. · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Cryoport reported Q1 2025, revenue of $41M, a net loss of $9M, diluted EPS of ($0.22).

For Q1 2025, Cryoport reported revenue of $41M, a net loss of $9M, diluted EPS was ($0.22). The filing highlights segment performance, liquidity, and management commentary on the period.

  • Revenue $41M.
  • Net loss $9M.
  • Diluted EPS ($0.22).

Headline financials

Total Revenue

$41M

Previous: $54.6M-24.8%
EPS (adj)

-$0.22

Previous: -$0.43+48.8%
Commercial Cell & Gene Therapy Revenue

$7.2M

No prior period
Adjusted EBITDA

-$2.82M

Previous: -$6.66M+57.7%
Global Clinical Trials Supported

711

Previous: 675+5.3%
Phase 1 Clinical Trials

304

Previous: 286+6.3%
Phase 2 Clinical Trials

328

Previous: 312+5.1%
Phase 3 Clinical Trials

79

Previous: 77+2.6%
Americas Clinical Trials

544

Previous: 518+5.0%
EMEA Clinical Trials

118

Previous: 112+5.4%
APAC Clinical Trials

49

Previous: 45+8.9%
Capital Expenditures

-$3.17M

Previous: -$4.01M+20.9%
Net Income

-$12M

Previous: -$18.9M+36.6%
Operating Income

-$9.48M

Previous: -$21.3M+55.4%
Gross Profit

$18.6M

Previous: $21.8M-14.4%

Revenue & EPS history

CryoPort · Revenue · Quarterly

$41M

Q1 2025-24.8%vs Q1 2024
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+2.2%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+8.5%

Avg return

30 days after

49%

28 / 57 earnings

Positive

+31.6%

Q4 2013

Best reaction

-33.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+19.4%+33.2%+58.2%
Q4 2025+2.9%-4.7%+3.3%
Q3 2025-8.2%-7.4%+3.5%
Q1 2025+23.4%+23.3%+23.7%
Q4 2024+30.6%-7.1%+5.7%
Q3 2024-3.6%-0.9%-8.6%
Q2 2024+3.9%+10.0%+9.8%
Q1 2024-17.5%-16.7%-30.6%
Q4 2023-12.3%-7.3%+10.3%
Q3 2023+8.9%+8.4%+46.7%
Q2 2023-0.2%+1.2%-5.0%
Q1 2023+13.9%+4.5%-6.3%
Q4 2022+13.7%+9.9%+15.3%
Q3 2022-33.8%-35.7%-26.5%
Q2 2022+6.8%+5.2%-16.1%
Q1 2022-8.5%-14.6%-2.8%
Q4 2021+9.3%+7.0%+1.9%
Q3 2021-1.0%-1.2%-22.8%
Q2 2021-1.5%-3.6%+2.9%
Q1 2021+9.0%+11.6%-2.4%
Q4 2020-0.7%-11.7%-12.5%
Q3 2020+5.0%+24.2%+12.8%
Q2 2020-2.0%-5.0%+55.5%
Q1 2020+2.0%+17.0%+22.6%
Q4 2019+2.1%+0.8%-11.9%
Q3 2019+1.4%+3.9%+5.6%
Q2 2019+19.7%+24.5%+2.3%
Q1 2019+12.5%+12.5%+17.7%
Q4 2018-0.6%+6.6%+22.3%
Q3 2018-1.0%-9.4%-2.0%
Q2 2018-1.6%-14.7%-6.5%
Q1 2018+11.8%+23.0%+67.4%
Q4 2017+3.8%+6.4%-7.0%
Q3 2017-15.1%-22.9%-10.5%
Q2 2017-2.0%+3.6%+28.6%
Q1 2017+8.2%+9.0%+46.9%
Q4 2016+23.7%+9.0%+23.7%
Q2 2016-7.5%
Q1 2016+10.2%
Q4 2015-3.0%
Q3 2015+7.5%
Q2 2015-14.4%
Q1 2015-2.2%
Q4 2014+6.4%
Q3 2014-5.6%
Q4 2013+31.6%
Q3 2013-8.0%
Q2 2013+5.3%
Q1 2013+0.0%
Q4 2012-3.1%
Q3 2012-10.8%
Q2 2012-8.0%
Q1 2012-2.7%
Q1 2010+11.2%
Q3 2009+1.4%
Q2 2009-2.8%
Q1 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro